Hamdi Sati

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 231 citations · Full text

Regenerative Medicine, Cell Therapy, Transplantation +7

Expression of interleukin‐1β and tumour necrosis factor‐α in plasma cells from patients with multiple myeloma

Hamdi Sati, M. Greaves, Jane F. Apperley et al. · British Journal of Haematology · 1999 · 92 citations · Full text

Pamidronate causes apoptosis of plasma cells <i>in vivo</i> in patients with multiple myeloma

Sharon Gordon, Miep Helfrich, Hamdi Sati et al. · British Journal of Haematology · 2002 · 62 citations

Incidence and associations of acute renal failure complicating high‐dose intravenous immunoglobulin therapy

Hamdi Sati, R. Ahya, Heather Watson · British Journal of Haematology · 2001 · 62 citations · Full text

Glomerular Disease, Immunotherapy, Pretreatment Renal Impairment +19